July 24, 2025

Addgene Announces Strategic Partnership with Promega to Launch Plasmid Collection

Addgene Announces Strategic Partnership with Promega to Launch Plasmid Collection

Promega Plasmid Collection, available through Addgene, equips industry and academic researchers with powerful bioluminescent assays that provide deeper insights into endogenous cellular biology

Watertown, MA USA. (July 15, 2025)

Addgene, a purpose-driven organization helping scientists conduct experiments with greater ease, speed, and reproducibility, today announced a strategic partnership with Promega to expand Addgene’s vast plasmid repository with the launch of the Promega Plasmid Collection. This new offering provides industry and academic researchers broad access to reliable, high-value plasmids designed for studying target engagement, protein-protein interactions, and targeted protein degradation, unlocking powerful insights critical to drug discovery and other biological breakthroughs.

“Expanding access to high-quality research materials is central to our work at Addgene, and this partnership with Promega signals a key step forward in our efforts to realize this mission,” said Chonnettia Jones, Ph.D., President and Executive Director of Addgene. “The Promega Plasmid Collection not only diversifies our catalog with novel plasmid offerings, it also builds on Addgene’s growing collection of materials available to industry researchers. I look forward to seeing the scientific progress made possible by the broad availability of these valuable tools.”

The initial launch of the Promega Plasmid Collection includes 300 plasmids available as traditional bacterial format or as purified DNA – a new service offering that strengthens Addgene’s growing product portfolio. Sourced from the Promega Early Access Program, the Promega Plasmid Collection will provide researchers worldwide with high-quality materials that can be leveraged for drug discovery and elucidating pathway biology.

Under the terms of the partnership, Addgene will store and distribute the plasmids provided by Promega – applying its hallmark quality controls, customer support and legal approvals to all orders.

“We are excited to collaborate with Addgene to increase access to plasmids developed through decades of innovation in bioluminescent technologies at Promega,” said Vanessa Ott, Senior Director of Life Science Product Management & Marketing at Promega. “Designed through real-world assay development, these tools offer performance and reliability. This partnership enables researchers to integrate the plasmids into their workflows more efficiently and helps translate ideas into answers more quickly across academic and industrial research.”

Scientists can now access the Promega Plasmid Collection through the material pages in Addgene’s online catalog, providing researchers with fast and easy access to reliable, quality-controlled plasmids – streamlining cell assay workflows.

The collection will continually expand, with an estimated 300 additional plasmids already planned for release in the coming months. For more information, visit Addgene’s Promega Plasmid Collection page.


About Promega Corporation 

Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s portfolio of over 4,000 products supports a range of life science work across areas such as cell biology; DNA, RNA and protein analysis; drug development; human identification and molecular diagnostics. These tools and technologies have grown in their application over the last 45 years and are used today by scientists and technicians in labs for academic and government research, forensics, pharmaceuticals, clinical diagnostics and agricultural and environmental testing. Promega is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors.

About Addgene

Addgene is a purpose-driven organization committed to accelerating discovery and innovation by helping scientists conduct experiments with greater ease, speed, and reproducibility. We are pioneers in scientific sharing, providing a vast catalog of expertly curated and quality-controlled plasmids developed by researchers around the world. We offer viral vector and recombinant antibody services built from the same trusted approach. Our dedicated team reduces barriers to scientific progress by facilitating material transfers and providing world-class educational resources. At Addgene, we care about building a globally connected scientific community collaborating and sharing seamlessly to unlock the full potential of research. For more information, visit https://www.addgene.org.

Our latest News

discover more
Workflow Optimisation in the Laboratory: Premiere of the smartLabs Summit in Heidelberg

Workflow Optimisation in the Laboratory: Premiere of the smartLabs Summit in Heidelberg

On September 24, 2025, the smartLabs Summit will open its doors for the first time in Heidelberg – an event dedicated to practical innovation, digitalization, and automation in laboratories. The Summit will take place at BioLabs Heidelberg (Nicola-Tesla Straße 1–3, 69124 Heidelberg) and offers a full program from 1:00 to 7:30 p.m. Initiated by the […]

DFG awards Heidelberg research project on early detection of spinal degeneration nearly €250,000 in funding

DFG awards Heidelberg research project on early detection of spinal degeneration nearly €250,000 in funding

The aim of the project is to use special quantitative MRI to visualize early changes in the intervertebral disc and enable timely treatment. Ultrashort echo time (UTE) MRI opens up completely new approaches to preventive imaging that are difficult or impossible to achieve with conventional MRI methods. Full text in German below. DFG fördert Heidelberger […]

Glioblastoma study shows: Molecular diagnostics could enable targeted therapies without delay

Glioblastoma study shows: Molecular diagnostics could enable targeted therapies without delay

Researchers from Heidelberg University’s Medical Faculty, the German Cancer Research Center (DKFZ), and the National Center for Tumor Diseases (NCT) in Heidelberg have tested the use of targeted drugs in the initial treatment of newly diagnosed glioblastoma, an extremely aggressive brain tumor, in the multicenter study “NCT Neuro Master Match (N2M2)”. Of the five drugs […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp